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Intrathecal Morphine for Laparoscopic Segmental Colonic
Resection as Part of an Enhanced Recovery Protocol
A Randomized Controlled Trial
Mark V. Koning, MD,*† Aart Jan W. Teunissen, MD,‡ Erwin van der Harst, MD, PhD,§
Elisabeth J. Ruijgrok, PhD,¶ and Robert Jan Stolker, MD, PhD†
Background andObjectives:Management of postoperative pain after
laparoscopic segmental colonic resections remains controversial. We
compared 2 methods of analgesia within an Enhanced Recovery After
Surgery (ERAS) program. The goal of the study was to investigate whether
administration of intrathecal bupivacaine/morphine would lead to an
enhanced recovery.
Methods: A single-center, randomized, double-blind controlled trial was
performed (NL43488.101.13). Patients scheduled for laparoscopic segmental
intestinal resections were considered. Exclusion criteria were patients in whom
contraindications to spinal anesthesia were present, conversion to open
surgery, and gastric and rectal surgery. The intervention group received
single-shot intrathecal bupivacaine/morphine (12.5 mg/300 μg), with an
altered dose for older patients. The control group received a sham pro-
cedure and a bolus of piritramide (0.1 mg/kg). Both groups received
standardized general anesthesia and a patient-controlled intravenous
analgesia pump as postoperative analgesia. All patients were treated
according to an ERAS protocol. A decrease in days to “fit for dis-
charge” was the primary outcome.
Results: Fifty-six patients were enrolled. Intervention group patients were
fit for discharge earlier (median of 3 vs 4 days, P = 0.044). Furthermore,
there was a significant decrease in opioid use and lower pain scores on
the first postoperative day in the intervention group. There were no differ-
ences in adverse events (except for more pruritus), time to mobilization,
fluid administration, or patient satisfaction.
Conclusions: This randomized controlled trial shows that intrathecal
morphine is amore effective method of postoperative analgesia in laparoscopic
surgery than intravenous opioids within an ERAS program. Recovery is faster
and less painful with intrathecal morphine. Other studies have confirmed these
results, although data on faster recovery are new and require confirmation in
future trials.
Clinical Trial Registration: This study was registered at ClinicalTrials.
gov, identifier NCT02284282.
(Reg Anesth Pain Med 2018;43: 166–173)
Enhanced Recovery After Surgery (ERAS) programs havechanged postoperative management for abdominal surgery
in the past decade. One of the recommendations in an ERAS
protocol for colorectal surgery is to limit opioid use via administra-
tion of multimodal analgesics, including regional anesthesia tech-
niques.1 Thoracic epidural analgesia is recommended for open
surgery; however, its use in laparoscopic surgery is associated with
a prolonged length of hospital stay due to delayed mobilization.2,3
Pain after laparoscopic surgery is intense, but relatively
short-lived when compared with open surgery, and the analgesia
should be tailored accordingly.4 Two common methods for post-
operative analgesia in laparoscopic surgery are systemic opioids
per requisite (eg, patient-controlled intravenous analgesia [PCIA])
or intrathecal morphine.2,5,6 The benefit of intrathecal morphine
is limited systemic uptake due to its hydrophilic properties and
thus a minor effect on bowel motility. Proclaimed disadvantages
include the risk of an intrathecal injection, pruritus, and delayed
respiratory depression.7,8 However, when a low dose of morphine
is used, there seems to be no more respiratory depression than
with systemic opioids.7 Patient-controlled intravenous analgesia
has the benefit that the dose of opioids is matched to the patient's
need, although its analgesic effect is limited by the patient's under-
standing and the adverse effects of the opioid.9,10
Previous studies on laparoscopic colonic resections have
shown a decrease in systemic opioid use with an increase of quality
of analgesia for intrathecal morphinewhen compared with PCIA.2,5,6
However, recoverywasmeasured only as length of hospital stay, and
recovery protocols were not standardized. We therefore designed
a confirmation trial with a few methodological adaptations in
an existing ERAS program to investigate whether intrathecal
bupivacaine and morphine can increase the speed of recovery
after laparoscopic colonic resections. These adaptations include
higher intrathecal morphine dose, similar postoperative analgesia,
fluid-restrictive management rather than goal-directed fluid
management, predefined “fit for discharge” (FFD) criteria, and
a longer follow-up period. We hypothesized that intrathecal
bupivacaine and morphine would enhance the speed of recovery
by decreasing systemic opioid utilization and concomitant systemic
adverse effects.
METHODS
Study Design
The SALMON study (SpinAL MOrphiNe) was an
investigator-initiated, single-center, randomized trial per-
formed in a large teaching hospital. The study was approved by
the ethics committee of Maasstad Hospital (Toetsingscommissie
Wetenschappelijk Onderzoek Rotterdam, the Netherlands,
NL43488.101.13) and CCMO (Dutch abbreviation for Central
Committee on Research InvolvingHuman Subjects). Patients pro-
vided written informed consent before enrollment. The study was
registered as NCT02284282 at ClinicalTrials.gov on November 6,
2014, and as NTR4870 at trialregister.nl on October 29, 2014.
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Participants
All patients who were scheduled for laparoscopic gastroin-
testinal surgery between October 2014 and October 2016 were
asked to participate. Exclusion criteria were as follows:
1. rectal and bariatric surgery;
2. contraindications to spinal anesthesia (eg, severe aortic steno-
sis, increased intracranial pressure, coagulation disorders);
3. contraindications to study medication (allergy for morphine,
local anesthetics [amides], nonsteroidal anti-inflammatory
drugs, paracetamol, or glomerular filtration rate <30 mL/min);
4. conversion to an open procedure; and
5. scheduled postoperative intensive care unit admission.
Patients who were considered eligible for the study were
informed on the preoperative screening unit with written and oral
information.Within aweek, the patients were called for further ex-
planation and definitive inclusion. After inclusion of 2 patients for
gastric resection, we concluded that this type of surgery has a dif-
ferent recovery profile than segmental colonic resections, and we
eliminated them from analysis.
Randomization, Allocation, and Blinding
Randomization was conducted by using sealed, opaque enve-
lopes. An independent colleague randomized these envelopes in
blocks of 6 with a ratio of 1:1. These envelopes were stacked
and stored. The upper envelope was taken by the attending anes-
thesiologist when an included patient arrived on the preparation
ward. The patient, the surgical team, the nurses on the ward, and
the researchers were all blinded. Only the attending anesthesiology
team and the nurse on the recovery ward were aware of the random-
ization, in case therewas an emergency. They were instructed not to
tell the patient in which group he/she was allocated.
Study Protocol
All patients were prepared according to the ERAS protocol,
consisting of a carbohydrate drink the night before surgery and
no bowel preparation; 1000mg intravenous (IV) cefazolin was ad-
ministered 30 minutes before surgery. No sedative premedication
was given.
In the operation theater, the patients received standard mon-
itoring (pulse oximetry, 3-lead electrocardiogram, automatic non-
invasive blood pressure measurements every 3 minutes). After the
time-out procedure, the surgical team left the theater for blinding.
According to the envelope, the patient received either an in-
trathecal injection of bupivacaine/morphine or a sham procedure.
In both cases, the patient was placed in an upright sitting position,
and the skin over the lumbar region of the back was cleaned with
chlorhexidine, and sterile drapes were placed.
For the intrathecal injection, the skin was infiltrated with
3 mL of lidocaine 1%. A sterile 27-gauge pencil-point needle
(Pencan; Braun Melsungen AG, Melsungen, Germany) was used
to enter the intrathecal space at the L2–3 or L3–4 interspace. After
obtaining cerebrospinal fluid, medication was administered
through a single injection; 12.5 mg isobaric bupivacaine and
300 μg morphine in 5 mL were administered when the age of
the patient was younger than 76 years, and 10 mg isobaric
bupivacaine and 240 μg morphine in 4 mL were given when the
age was older than 75 years.
For the sham procedure, the skin was infiltrated with 3 mL of
lidocaine 1%. After this, the anesthesiologist pressed on the skin
with a finger and talked as if he/she gave an intrathecal injection.
The patients who were randomized to the control group received
0.1 mg/kg piritramide intravenously during surgery, which was
common practice in our hospital.
Standardized general anesthesia was administered immedi-
ately after the puncture. After preoxygenation, 0.4 μg/kg sufentanil,
2 mg/kg propofol, and 0.6 mg/kg of rocuroniumwere administered,
and the trachea was intubated. Sterile drapes were placed after
positioning of the patient, and the surgery was started as soon as
possible. Pneumoperitoneum was installed by needle insufflation
through a small periumbilical incision with an insufflation pres-
sure of 14 mm Hg and changed at the discretion of the surgeon.
Standard IV medication of 1000 mg paracetamol, 1000 mg
metamizol, 0.625 mg droperidol, and 4 mg ondansetron were
given before the end of surgery. Ten micrograms of IV sufentanil
was administered when an increase in heart rate or blood pressure
of greater than 10% occurred compared with a stable phase during
surgery. Ten milligrams of IV rocuronium was administered when
ventilator dyssynchronization or abdominal wall contraction oc-
curred that remained after 10 μg IV sufentanil. Vasoactive medica-
tion was given at the discretion of the executive anesthesiologist
(ie, phenylephrine, ephedrine, and norepinephrine). Every patient
received an IV drip with 500mL lactated Ringer's solution to keep
an open IV line, and the targeted fluid balance was less than
+750 mL. Blood loss was compensated with a blood transfusion
according to the Dutch national guidelines, maintaining the hemo-
globin level between 6.4 and 9.4 g/dL or Voluven (HES 130/0.4
[6%]; Fresenius Kabi, Bad Homburg, Germany) in a 1:1 manner,
at the discretion of the anesthesiologist.
After completion of surgery, patients were allowed to wake
up and were extubated in the operation theater. Nasogastric tubes
were removed. A train-of-4 measurement was done in order to
exclude residual relaxation. If necessary, rocuronium was antago-
nized with atropine/neostigmine or sugammadex at the discretion
of the anesthesiologist.
Standard monitoring continued in the recovery ward. Pain
scores (on a numerical rating scale [NRS]) were noted at admis-
sion to and discharge from the recovery ward and regularly at a
10-minute interval by the recovery nurse; 2.5 mg piritramide IV
was administered when the patient reported an NRS of greater
than 4 and repeated every 10 minutes if necessary. Nausea was
treated with a repeated dose of 0.625 mg IV droperidol Intrave-
nous propofol 30mgwas available for complaints of pruritus. Dis-
charge from the recovery unit to the ward was allowed when the
patient was hemodynamically and respiratory stable, reported an
NRS of less than 4, and had a Glasgow Coma Scale score of
greater than 14. All patients received 2 L of oxygen per minute
by nasal cannula. Paracetamol 1000 mg 4 times a day, metamizol
1000 mg 4 times a day, and piritramide by PCIA system were
prescribed as postoperative analgesic management. The PCIA
was set up to give 1 mg of piritramide per bolus with a lockout
time of 6 minutes. The PCIA system was stopped on the second
postoperative day. Four milligrams of ondansetron per requisite
was available for nausea, and 1 mg clemastine per requisite was
available for pruritus. All patients received daily macrogol 13.7 g as
a laxative.
An ERAS protocol has been fully functional for multiple
years on the ward. It consisted of early enteral feeding (eg, drinks
immediately on arrival on the ward, a small meal on the night of
surgery), early mobilization, and removal of the urinary catheter
the day after surgery.
Data Collection
Baseline characteristics and laboratory results were noted
from the patient data file. The anesthesia team was asked to fill
in a case record form during the surgery and the recovery phase.
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The patientswere asked to fill in a questionnaire 3 times a day regard-
ing pain scores (NRS 0–10), nausea (yes/no), pruritus (yes/no),
drowsiness (yes/no), and satisfaction regarding pain management
(0–3, where 0 is “very unsatisfied,” and 3 is “very satisfied”). They
were also asked to note the time for first drinks, first food, first full
meal, first mobilization, first flatus, and first bowel movement. This
was then converted to hours after discharge from the recovery room,
which was T = 0. An anesthetic nurse visited the patient daily for a
reminder of the questionnaire and for checking and explaining the
pain medication. The PCIA system was electronically checked for
demands and delivered boluses.
Outcomes
Primary outcomewas the number of days until FFD since the
day of the surgery (which is day 0). Fit for discharge was defined
as a patient who
1. was taking only oral pain medication,
2. was able to walk around in the room independently,
3. was tolerating a full oral diet and had bowel movements,
4. was hemodynamic and respiratory stable, and
5. had no drains or urinary catheters in situ.
Patients were checked for the criteria once a day during
morning rounds. This assessment continued during the admission,
even if the patient was FFD earlier.
Secondary outcomes included use of piritramide per PCIA in
milligrams, patient satisfaction, pain scores and occurrence of adverse
effects, difficulty of surgery, laboratory results, and adverse events.
Definitions
Time of surgery was defined as the time between start of
pneumoperitoneum and the start of emergence of anesthesia.
The time on the recovery ward was defined as the time between
arrival and the call to the ward for picking up the patient. A
conversion of surgical approach was defined as an unforeseen
change in incision. An ileus was defined as an insertion of a draining
nasogastric tube and nothing by mouth lasting more than 24 hours.
An anastomotic leakage was defined as an intra-abdominal infection
that required surgery or percutaneous drainage.
Statistical Analysis
A power analysis showed that we needed 46 subjects in order
to detect a difference in FFD from 5 ± 1 day to 4 ± 1 day with a
2-sided power of 90% and P = 0.05. We suspected a 20% loss
to follow-up, for which we added 10 patients. Therefore, we
needed a minimum of 56 patients, which we set to n = 60. The
values we used were in accordance with previous studies.11,12
We performed a per-protocol analysis. Data are described in
median (interquartile range) (range). Comparisons for non–normally
distributed outcomes were made by a Mann-Whitney U test. For or-
dinal data, a Fisher exact test was used. P = 0.05 was considered sta-
tistically significant. Values were calculated with SPSS version 21.0
(IBM, Armonk, New York), and graphics were made by GraphPad
Prism version 7.1 (GraphPad Software, San Diego, California).
RESULTS
Sixty patients were randomized. Two patients who were
randomized into the intervention group were treated as a control
because in 1 patient the study medication was unavailable and a
FIGURE 1. Flowchart of inclusion. See text for specifications.
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misconception occurred in the other patient. Becausewe performed
a per-protocol analysis, these patients were analyzed as a control
group. Two other patients in the control group were converted to
an open procedure because of adhesions and were excluded from
analysis. Patients with gastric resections (n = 2) were excluded from
analysis (see Methods). A flowchart is presented in Figure 1.
Baseline characteristics are presented in Table 1. There were
more sigmoidal resections in the intervention group, whereas
therewere more right-sided hemicolectomies in the control group.
Age and comorbidities were nonsignificantly different. For the in-
tervention group, all attempts for intrathecal injection succeeded,
because cerebrospinal fluid was obtained in all patients.
Primary Outcome Parameters
Patients in the intervention group were FFD earlier than pa-
tients in the control group (median, 3 [3–4] [1–28] vs 4 [3–5]
[2–25] days; P = 0.044). After 3 days, 16 patients (59%) in the in-
tervention group versus 10 patients (34%) were FFD (Fig. 2),
P = 0.056. No difference was detected for actual length of stay
(median, 4 [4–6] [1–33] vs 5 [4–7] [2–26]days; P = 0.270). No re-
gression to “not FFD” occurred in any patient when scored as being
FFD. Also, no readmissions occurred within 30 days after discharge.
Secondary Outcome Parameters
All patients were treated according to an ERAS protocol. No
difference was detected in time to first drinks, foods, meals, mobi-
lization, flatus, or defecation (Table 2).
Pain scores were lower in the intervention group on the first
postoperative day, as indicated by lower NRS scores (Table 3).
This effect was despite a lower opioid use per PCIA in the
intervention group. The difference in use of PCIA lasted for the
first 20 hours after surgery (Fig. 3). The difference in opioid use
occurred in the first 20 hours, which led to a difference in
piritramide dose of 9 mg (3–17 mg) (0–36 mg) versus 33 mg
(26–61 mg) (13–112 mg), P < 0.001. The difference was 15 mg
(4–25 mg) (0–60 mg) versus 44 mg (33–77 mg) (14–127 mg),
P < 0.001, after 48 hours. Only 5 patients used additional
opioids (10 mg long-acting oxycodone by mouth) when the
PCIA pump was removed: 1 patient (4%) in the intervention
group compared with 4 (14%, no difference, P = 0.353) in the
control group.
Patients in the intervention group received less intraoperative
sufentanil (30 [25–35] [15–50] vs 45 [35–50] [20–75]μg,
P < 0.001), had lower pain scores upon arrival on the recovery
(0 [0–3] [0–6] vs 4 [1–6] [0–9], P = 0.001), and had less pain
by discharge to the ward (0 [0–2] [0–3] vs 3 [2–4] [0–4],
P < 0.001). No difference was detected in difficulty for the sur-
geon, duration of surgery, duration on the recovery ward, blood
loss, or fluid administration.
Residual sensory block was tested in all intervention patients
and was detected below a median of Th10 (Th7–Th12) (none–L2).
No motoric blockade could be detected in any intervention patient.
More patients with intrathecal morphine had pruritus than
the control group (41% vs 8%, P = 0.001), although solely on
the first day (Table 3). Interestingly, none of the patients asked
for treatment of the pruritus. There was no difference detected in
nausea, drowsiness, or adverse events.
One patient in the control group died on the eighth postoper-
ative day because of septic shock. The focus for shock was most
likely to be an abdominal focus, although an autopsy was not per-
formed. Two patients in the control group were converted to an
open procedure. An ileus occurred in 3 patients (11%) in the inter-
vention group versus 5 patients (17%) in the control group (nonsig-
nificant), and in both groups, there was 1 patient with anastomotic
leakage. Other nonanastomotic leakage infections occurred in
3 patients (10%) in the control group versus 2 patients (7%) of
the intervention group (nonsignificant). There were 3 other minor
complications in the control group (severe pain requiring rescue
medication [n = 1], exacerbation chronic obstructive pulmonary
disease [n = 1], and severe hypokalemia [n = 1]), whereas no other
complications were noted in the intervention group.
No statistically significant differences were found between
groups regarding patient satisfaction, even though a trend was ob-
served on the day of surgery (40% vs 71%were very satisfied with
the analgesia, P = 0.071, and 13% vs 0% were unsatisfied regard-
ing pain control, P = 0.236) (Table 3).
DISCUSSION
This study shows that a single intrathecal injection of
bupivacaine/morphine when compared with patients on systemic
opioids leads to a faster recovery in a laparoscopic surgery en-
hanced recovery protocol. Less PCIA opioids were used in the
first 20 hours after laparoscopic surgery, and patients reported
TABLE 1. Baseline Characteristics
Control (n = 29) Intervention (n = 27)
Male, n (%) 15 (51.7) 18 (66.7)
Age, y 69 (62.5–77) (41–85) 68 (61–71) (49–80)
Length, cm 174 (168.5–181) (158–189) 178 (170–182) (163–200)
BMI, kg/m2 27.3 (24.9–30) (21.1–37.2) 27.5 (25.6–30.6) (21.1–50.2)
ASA class (1/2/3), n (%) 6/17/6 (21/59/21) 8/12/7 (30/44/26)
Time of start of surgery, h:min 11:30 (9:15–13:00) (8:00–15:30) 10:30 (8:30–12:30) (8:00–14:00)
Type of surgery, n (%)
Left hemicolectomy 2 (7) 2 (7)
Right hemicolectomy 20 (69) 14 (52)
Ileocoecal resection 1 (3) 1 (4)
Sigmoidal resection 6 (21) 10 (37)
Malignancy as indication, n (%) 26 (90) 23 (85)
Data are presented as n (%) or median (IQR) (range).
ASA indicates American Society of Anesthesiologists; BMI, body mass index.
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lower pain scores with intrathecal morphine. There was a higher
incidence of pruritus. Our study was unable to detect a difference
in patient satisfaction.
The faster recovery is displayed in the fact that patients were
FFD earlier.We believe that meeting the FFD criteria reflects recov-
ery better than the length of stay, because the latter is also influenced
by social or nonmedical decisions (eg, no place available in the
nursing home, discharge preferred during workdays). Our FFD
criteria were in accordance with international consensus.13
The reason for the faster recovery is unclear, because both
groups had similar adherence to the ERAS protocol. The difference
in faster recovery could be explained by the preoperative fitness,
although there are no signs that differences in preoperative fitness
played a role, because the groups were well randomized in other
aspects. However, the use of systemic opioids and the pain scores
were lower in the intervention group, which could lead to a difference
in the extent ofmobilization or enteral feeding. For example, firstmo-
bilization could have been 5 steps in the room or a walk to the coffee
machine in the hall. Unfortunately, this was not measured.
Our results differ from the study of Wongyingsinn et al,6
which did not find a faster recovery. That studymeasured the actual
length of hospital stay instead of FFD criteria, with the aforemen-
tioned limitations. Furthermore, different postoperative regimens
for analgesia were used (PCIAvs oral oxycodone), and a different
dose of intrathecal morphine was used. Still, the recovery profile
was deemed very comparable in regard to pain scores, opioid use,
and duration of intense pain.
A large variance in PCIA use was observed in the control
group, whereas in the intervention group the variance was less.
Still a substantial amount of systemic piritramide was saved in
the intervention group during the first 20 hours, which indicates
the effect of a single shot of intrathecal morphine. Moreover, pain
scores were lower in the intervention group, despite the same
availability of PCIA piritramide. This indicates that even though
PCIA is used, patients still have room left for lowering the pain
scores. Explanations for this observation are either the patient
does not need a lower pain score or the PCIA is unable to achieve
lower pain scores because of patient knowledge gaps, inadequate
FIGURE 2. Patients in the intervention group were earlier FFD (4 [3–5] [2–25] vs 3 [3–4] [1–28] days; P = 0.044). The bars in the chart
correspond to the upper 2 rows in the table and represent the percentage of patients who met the FFD criteria per day. The dark lines
represent the cumulative percentage of patients who met the FFD criteria, and the light lines represent the cumulative percentage of the
aLOS. These lines correspond to the middle 2 and the lower 2 rows in the table, respectively. The table displays the percentages in a
numeric fashion. aLOS indicates actual length of stay; POD, postoperative day.
TABLE 2. Indicators of ERAS Adherence
Control Intervention P
Time to first drink 3 (1–5) (0–16) 2 (1–4) (0–19) 0.461
Time to first food 16 (9–19) (3–24) 14 (4–19) (1–24) 0.308
Time to first meal 19 (17–28) (14–66) 22 (16–24) (1–44) 0.826
Time to first mobilization 20 (17–23) (14–116) 20 (17–24) (8–48) 0.984
Time to first flatulence 42 (19–54) (0–100) 30 (21–45) (10–68) 0.306
Time to first defecation 65 (46–82) (22–96) 54 (46–68) (16–144) 0.510
Timing is presented in hours after discharge from the recovery ward. Data are presented as median (IQR) (range).
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medication or settings of the PCIA, or occurrence of adverse
effects. Unfortunately, this study was not set up to investigate this.
Pain scores and PCIA piritramide use were similar after the
first day, indicating that either the effect of intrathecal morphine
or the pain of laparoscopic surgery has worn off.14,15 In both groups,
only small amounts of opioids were used after the first day, and no
rebound pain was observed during the follow-up period. These facts
suggest that the duration of analgesia of intrathecal morphine is ap-
propriate to cover the pain for this type of surgery.
Appropriate analgesia without serious adverse effects and
delaying recovery is the primary goal of analgesia in the ERAS pro-
gram.1 In this study, this dose proved to provide appropriate analgesia
during the first 24 hours. Furthermore, apart from pruritus, neither
significant adverse effects nor any adverse events were observed, al-
though the number of patientsmay be too low for detection. The dose
of 300 μg of morphine was chosen based on a meta-analysis and a
review.7,16 To our knowledge, a dose-finding study of intrathecal
morphine for laparoscopic surgery has not been published.
Ten to 12.5 mg of bupivacainewas added to enhance intraop-
erative analgesia, and its effect is displayed in the lower intraoper-
ative sufentanil use. It could also have contributed to the lower
pain scores on the recovery ward. A preemptive analgesic effect
might be involved as well, although there are no data available
to support this claim. However, because we observed no adverse
events related to bupivacaine (eg, prolonged motor blockade or
sympatholysis), we would recommend adding bupivacaine to the
intrathecal mixture.17 Common doses of vasopressors were used
in this study, and a fluid-restrictive management was still achieved
in both groups, without a significant difference between groups.
The intervention group suffered from a higher incidence of
pruritus, despite the use of prophylactic measures.7,18–20 Interest-
ingly, patients did not ask for medication to treat the pruritus, even
though it was available and prescribed on demand for them. A
trend toward more nausea on the first day for the intervention
group was observed, but this was reversed on the second postop-
erative day. Perhaps administration of dexamethasone at induction
of anesthesia and/or prescribing 5-HT3 antagonists at standardized
times rather than per requisite would alter the nausea.
A well-known adverse effect of intrathecal morphine is de-
layed respiratory depression.21,22 In this study, all patients re-
ceived supplemental oxygen by nasal cannula, and sedatives
were prohibited during the first night. None of the patients' vital
signs were monitored after discharge from the recovery ward.
We did not study respiratory frequency or oxygen saturation dur-
ing the first night, so we cannot comment on the occurrence of a
delayed respiratory depression; however, no clinically relevant
consequences were observed. This observation is in line with the
meta-analysis of Gehling and Tryba,7 which concluded that at less
than 500 μg intrathecal morphine does not cause serious respira-
tory adverse events. Another meta-analysis does warn for respira-
tory depression, but it did not investigatewhether there was a dose
dependency.8 A few case reports suggest respiratory depression
after intrathecal morphine with a dose lower than 500 μg, but it
is not clearly related to morphine as multiple sedatives were used
as well.23,24 Therefore, we prohibited sedative medication to pre-
vent an interaction with the intrathecal morphine.
We found no difference in patient satisfaction, which indi-
cates that both groups perceived pain levels to their expectations.
Although a trend was observed, it did not reach statistical signifi-
cance. We measured satisfaction on a nonvalidated 4-point scale,
which could be too insensitive to measure any effect. However,
in our opinion, a smaller effect is hardly clinically relevant.
This study has several strengths, which contribute to the
search for a fitting method of analgesia for laparoscopic colonic
resections.2,5,6,12 Its follow-up lasts for the total time of admission,
the departments were used to an ERAS program, the 2 study arms
received similar postoperative care, and it was a double-blind
TABLE 3. Patients' Self-reported Scores
Control Intervention P
Mean pain
scores
POD 0 2 (2–7) (0–7) 1.5 (0–4) (0–6) 0.075
POD 1 2.3 (1.3–4.3) (0.7–5.3) 0.3 (0–3.8) (0–6.3) 0.004
POD 2 1.7 (1.3–3) (1–4) 0.8 (0–2.5) (0–4.7) 0.147
POD 3 1.3 (0.7–2.3) (0–4) 0.3 (0–1.3) (0–3) 0.389
Nausea
POD 0 6 (24%) 11 (52%) 0.068
POD 1 11 (42%) 6 (24%) 0.237
POD 2 11 (44%) 6 (30%) 0.372
POD 3 8 (36%) 9 (42%) 0.760
Pruritus
POD 0 2 (8%) 9 (41%) 0.014
POD 1 1 (4%) 6 (26%) 0.044
POD 2 1 (4%) 1 (5%) 1.000
POD 3 0 (0%) 0 (0%) N/A
Drowsiness
POD 0 16 (64%) 9 (41%) 0.148
POD 1 10 (40%) 4 (17%) 0.117
POD 2 4 (16%) 0 (0%) 0.114
POD 3 1 (6%) 0 (0%) 1.000
Unsatisfied
POD 0 3 (13%) 0 (0%) 0.236
POD 1 3 (12%) 2 (9%) 1.000
POD 2 3 (12%) 1 (5%) 0.614
POD 3 1 (5%) 0 (0%) 1.000
Very satisfied
POD 0 10 (40%) 15 (71%) 0.071
POD 1 12 (48%) 14 (61%) 0.401
POD 2 14 (56%) 15 (72%) 0.363
POD 3 15 (68%) 15 (75%) 0.738
Mean pain scores were the mean NRS scores from 0 to 10 over 3 time
points during the day. Nausea, pruritus, and drowsiness were a yes or no
question, and incidence is reported. Satisfaction was asked on a 4-point
scale, fromwhich 0 and 1were defined as “unsatisfied,” and 2was “normally
satisfied.” “Very satisfied”was indicated by the number 3. Data are presented
as median (IQR) (range) or as n (%).
N/A indicates not applicable.
FIGURE 3. Cumulative use of piritramide per PCIA.
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study. Unlike Levy et al,2 we did not use goal-directed fluid man-
agement, but rather we used a fluid-restricted management and
early oral hydration. This was more in line with contemporary
guidelines for fluid management in patients without severe
cardiovascular comorbidity.25
This study has several limitations. First, we excluded the
converted surgeries, so we cannot comment on the effect of intra-
thecal morphine on laparotomy surgery. However, it seems rea-
sonable to assume that intrathecal morphine still has an
analgesic effect after open surgery during the first day and still ex-
erts an advantage in this setting. Second, we did not measure the
magnitude of mobilization, which could be the underlying explana-
tion for the faster recovery in the intervention group. Third, the
measurement of patient satisfaction may be too insensitive, as men-
tioned previously. Unfortunately, we did not use a quality-of-
recovery questionnaire, which is recommended by the European
Society of Anaesthesiology for measuring quality of recovery.
Fourth, allocation went wrong in 2 patients. Because it was a per-
protocol analysis, we analyzed these patients in the control group.
This mistake was due to implementation of the study in the daily
work and unrelated to the patient. Furthermore, the sample size is
relatively low, so a confirmatory trial is necessary, especially for
the faster recovery.
In addition, we did not measure the cost-effectiveness of the
intervention. The intervention will probably become cost-effective
when the actual length of stay is reduced, because the costs of an
admission day are higher than the intervention. Thus, additional
efforts are needed to reduce the actual length of stay in order to re-
duce the costs.
Further research should focus on a confirmatory trial using
fitness for discharge as the primary outcome, evaluating extent
of mobilization as an explanation for how intrathecal morphine
enhances recovery and to also clarify how the time between
FFD and actual discharge can be minimized. Also, given the large
variance of postoperative opioid use, investigations for which pa-
tients benefit most from this intervention should be initiated.
In conclusion, this randomized controlled trial shows that in-
trathecal bupivacaine/morphine provides a short-lasting analgesic
effect during the first postoperative day after laparoscopic surgery.
Most important, this method of analgesia leads to faster recovery,
lower pain scores, and less opioid use after laparoscopic gastroin-
testinal surgery when comparedwith patients on systemic opioids.
There is more pruritus in the intervention group, but no patient re-
quired treatment for this adverse effect.We recommend further re-
search regarding intrathecal bupivacaine/morphine within an
ERAS program, because recovery could be further enhanced with
this method of analgesia.
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